Pharma Focus Asia

Astellas Pharma Enters into Collaboration and Option Agreement with Cullgen

Thursday, June 15, 2023

Astellas Pharma and Cullgen have entered into a research collaboration and exclusive option agreement to discover multiple innovative protein degraders. 

This partnership aims to develop targeted protein degraders by combining Cullgen's uSMITE™ targeted protein degradation platform with Astellas' drug discovery capabilities.

Under the terms of the agreement, Cullgen and Astellas will conduct joint research activities to identify potential compounds for clinical development. Following this research phase, Astellas will have the exclusive option to licence the rights for clinical development and commercialisation of the protein degrader compounds that are discovered during the collaboration.

This collaboration is expected to bring together the cutting-edge research capabilities of both companies, creating synergies that will contribute to the expansion of Astellas' portfolio. Ultimately, the development of new therapeutics through protein degradation could address significant unmet medical needs and benefit patients.

Cullgen's uSMITE™ platform is based on novel E3 ligands, which play a crucial role in protein degradation. By leveraging this platform along with Astellas' expertise, the two companies aim to identify clinical development candidates for protein degraders.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024